JEFFREY HANSEN: Open Payments
NPI 1356410419 · VANCOUVER, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$491,853 in 590 payments from 13 companies in 2025. Trend: 2023 $433,120 · 2024 $462,937 · 2025 $491,853
Speaker / faculty: $335,993Travel & lodging: $65,386Consulting: $52,868Honoraria: $25,025Food & beverage: $12,569Education: $12
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 115 | $112,281 |
| ABBVIE INC. | 96 | $91,132 |
| Janssen Pharmaceuticals, Inc | 56 | $62,513 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 65 | $52,373 |
| Teva Pharmaceuticals USA, Inc. | 54 | $49,715 |
| Axsome Therapeutics, Inc. | 47 | $28,903 |
| Otsuka America Pharmaceutical, Inc. | 52 | $28,764 |
| E.R. Squibb & Sons, L.L.C. | 38 | $26,654 |
| Alkermes, Inc. | 26 | $20,361 |
| Vanda Pharmaceuticals Inc. | 29 | $18,975 |
Products named: INGREZZA, VRAYLAR, SPRAVATO, CAPLYTA, AUSTEDO XR, Auvelity, REXULTI, COBENFY.
Industry payments across WA — which companies pay providers there.
